PH10 Drug Market

"PH10 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about PH10 for Major Depressive Disorder (MDD) in the seven major markets. A detailed picture of the PH10 for MDD in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the PH10 for MDD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PH10 market forecast analysis for MDD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in MDD.

 

PH10 Drug Summary

PH10 is an investigational first-in-class, odorless, fast-acting synthetic neurosteroid with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of MDD that can be conveniently self-administered at home. Upon self-administration, a non-systemic microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure, or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and esketamine.

 

Scope of the PH10 Drug Market Report

The report provides insights into:

• A comprehensive product overview including the PH10 description, mechanism of action, dosage and administration, research and development activities in MDD.

• Elaborated details on PH10 regulatory milestones and other development activities have been provided in this report.

• The report also highlights the PH10 research and development activities in MDD across the United States, Europe and Japan.

• The report also covers the patents information with expiry timeline around PH10.

• The report contains forecasted sales of PH10 for MDD till 2032.

• Comprehensive coverage of the late-stage emerging therapies for MDD.

• The report also features the SWOT analysis with analyst views for PH10 in MDD.

 

PH10 Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

PH10 Analytical Perspective by DelveInsight

• In-depth PH10 Market Assessment

This report provides a detailed market assessment of PH10 for MDD in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data of PH10.

• PH10 Clinical Assessment

The report provides the clinical trials information of PH10 for MDD covering trial interventions, trial conditions, trial status, start and completion dates.

 

PH10 Drug Market Report Highlights  

• In the coming years, the market scenario for MDD is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   

• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PH10 dominance.

• Other emerging products for MDD are expected to give tough market competition to PH10 and launch of late-stage emerging therapies in the near future will significantly impact the market. 

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PH10 in MDD.

• Our in-depth analysis of the forecasted sales data of PH10 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PH10 in MDD. 

 

Key Questions

• What is the product type, route of administration and mechanism of action of PH10?

• What is the clinical trial status of the study related to PH10 in MDD and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PH10 development?

• What are the key designations that have been granted to PH10 for MDD?

• What is the forecasted market scenario of PH10 for MDD?

• What are the forecasted sales of PH10 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  

• What are the other emerging products available and how are these giving competition to PH10 for MDD?

• Which are the late-stage emerging therapies under development for the treatment of MDD?